SUN PHARMaceuticals has received approval for the new drug application #ANDA079169, a development that is poised to expand the company’s footprint in the specific therapeutic sector by introducing a generic alternative. This accolade positions SUN PHARM to capture a significant share of the market, driven by the increased accessibility and cost efficiency of the new product.